Eli Lilly and Company (NYSE: LLY), a global healthcare company, has dosed patients in the first study of LY-CoV555 intended to prevent COVID-19, it was reported on Monday.
The product has been developed as a result of the collaboration between Lilly and AbCellera. It is a potent, neutralising IgG1 monoclonal antibody directed against the SARS-CoV-2 spike protein. The first patients have been dosed at major medical centres in the United States, including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
The firm aims to study the drug in a preventative setting, concentrating on vulnerable patient populations who historically are not optimal candidates for vaccines. Should Phase 1 results show the antibody can be safely administered, Lilly expects to move into the next phase of testing, studying LY-CoV555 in non-hospitalised COVID-19 patients.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval